DNER, an epigenetically modulated gene, regulates glioblastoma-derived neurosphere cell differentiation and tumor

Peng Sun1, Shuli Xia, Bachchu Lal

  • 1Department of Neurology, The Johns Hopkins University School of Medicine and The Hugo W. Moser Research Institute at Kennedy Krieger, Baltimore, Maryland 21205, USA.

Insights

Histone deacetylase inhibitors reduce glioblastoma stem-like cell growth and promote differentiation. A key mediator, Delta/Notch-like epidermal growth factor-related receptor (DNER), exhibits tumor-suppressive effects via noncanonical Notch signaling.

Area of Science:

  • Neuro-oncology
  • Cancer Stem Cell Biology
  • Epigenetics

Background:

  • Glioblastoma (GBM) stem-like cells drive tumor growth and therapeutic resistance.
  • Understanding the regulation of these stem-like cells is crucial for developing effective treatments.

Purpose of the Study:

  • To investigate the role of histone-modifying agents in regulating GBM stem-like cell phenotype and tumor-promoting capacity.
  • To elucidate the mechanisms underlying GBM stem-like cell regulation.

Main Methods:

  • Utilized established and primary glioblastoma-derived neurosphere lines.
  • Administered histone deacetylase (HDAC) inhibitors.
  • Analyzed the expression and function of Delta/Notch-like epidermal growth factor-related receptor (DNER).
  • Evaluated effects on cell growth, differentiation, apoptosis, and tumor xenograft formation in vivo and in vitro.

Main Results:

  • HDAC inhibitors suppressed growth, induced differentiation, and promoted apoptosis in GBM neurosphere cells.
  • HDAC inhibition upregulated DNER expression.
  • DNER inhibited GBM neurosphere growth, induced differentiation, and reduced tumor xenograft formation.
  • DNER's tumor-suppressive effects contrast with canonical Notch signaling's known tumor-promoting role.

Conclusions:

  • Noncanonical Notch signaling, mediated by DNER, plays a role in regulating neoplastic stem-like cells.
  • HDAC inhibitors and DNER represent potential therapeutic strategies for targeting glioblastoma stem-like cells.
  • Findings suggest novel treatment avenues for glioblastoma and other solid malignancies.